Skip to content

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research

Marianna Graziosi, Gabrielle Agin-Liebes, Mary P Cosimano, Alicia Danforth, Gerhard Gründer, Natalie Gukasyan, Friederike Holze, Benjamin Kelmendi, Michael Koslowski, Stephen Ross, Karina Sergi, Jordan Sloshower, Lukasz Smigielski, Dea Siggaard Stenbæk, Brandon Weiss, Max Wolff, David B. Yaden, Anna Owen, Scott T Aaronson, K. Clint Allen, Frederick S. Barrett, Michael P. Bogenschutz, Robin Carhart-Harris, Terence H. W. Ching, Alan K. Davis, Albert Garcia‐romeu, Roland R. Griffiths, Charles S. Grob, Keith G. Heinzerling, Peter S. Hendricks, David Horton, Matthew W. Johnson, Stéphanie Knatz Peck, Matthias E. Liechti, Lea J. Mertens, Francisco Moreno, Sandeep M. Nayak, Christopher R. Nicholas, Katrin H. Preller, Nathalie M. Rieser, Franz X. Vollenweider, Mary E. Yaden

Psychedelic Medicine January 20, 2025 DOI: 10.1089/psymed.2024.0019 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Reflexive thematic analysis Peer reviewed
Population Psilocybin study materials from healthy and therapeutic populations
Topics Psilocybin
Keywords Field mathematics
Citations 9
Key points Psychoeducation documents from psilocybin studies commonly emphasize biological and physical safety, psychological safety, setting, and expectancies, with biological and psychological safety prioritized across all sites.

Abstract

Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for personal and family history of potential contraindications, and psychoeducational preparation with psychological support. Research settings typically provide psychoeducation to participants verbally and in writing (e.g., informed consent), and such documents and conversations can provide safety-related information—but may also introduce a wide range of expectancies. Such expectancies might involve the specific character of the acute subjective effects of psychedelics, possible side effects, and anticipated outcomes.

Methods: To better understand the content of this psychoeducation, we gathered study materials from many psilocybin studies conducted in the past two decades in healthy and therapeutic populations. We conducted a reflexive thematic analysis to better understand these documents.

Results: While these documents varied substantially between studies, we identified themes intended to lower levels of risk and optimize therapeutic effects from psychedelic treatments. The most frequently coded themes related to (1) biological and physical safety, (2) psychological safety and well-being, (3) aspects of setting, and (4) potential for expectancies. Prioritizing biological and psychological safety was evident in the materials from all sites. Furthermore, we identify potential contributors to expectancy unrelated to safety and suggest that these extrapharmacological elements be studied systematically in future research. Conclusions : Ideally, future research should strive to maximize safety while attempting to minimize extraneous expectancies.

Comparable studies

Other qualitative studies on psilocybin, most cited first.

Study Year Design Participants
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression enrolled in an open-label trial of psilocybin 2017 Qualitative study n = 20
Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis Adults aged 22 to 69 with clinically elevated anxiety associated with a cancer diagnosis 2017 Qualitative study n = 13
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts Participants who completed a psilocybin-facilitated smoking cessation pilot study 2018 Qualitative follow-up study using semi-structured interviews and thematic analysis n = 12
Response of cluster headache to psilocybin and LSD Cluster headache patients who used psilocybin or LSD 2006 Qualitative study n = 53
Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress Adult participants with clinically elevated anxiety associated with a cancer diagnosis 2017 Qualitative study using interpretative phenomenological analysis n = 13

Citations in the library

Cited by 8

and 3 more in the library

Cites 78

and 73 more in the library

Explore topics